Sanjay Bhagani

Also affiliated with The Royal Free Hospital, Government of the United Kingdom, University Hospitals of Leicester NHS Trust, University College London

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 12 papers. Top paper: “Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial”.

Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial

The Lancet Respiratory Medicine(2022)10.1016/s2213-2600(22)00215-6

N/A

4.5DataRank · unranked

128 citations

Adit A. Ginde, Roger Paredes, Thomas A. Murray, Nicole Engen, Greg Grandits +95 more

Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial

The Lancet(2022)10.1016/s0140-6736(22)00101-5

N/A

3.1DataRank · unranked

77 citations

Jacqueline Nordwall, Abdel G. Babiker, Andrew Phillips, David M. Vock, Nnakelu Eriobu +83 more

Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection

Journal of Hepatology(2021)10.1016/j.jhep.2021.04.056

N/A

1.3DataRank · unranked

49 citations

Sanjay Bhagani, Marc van der Valk, Juergen Rockstroh, Andri Rauch, Christine Thurnheer +33 more

Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA)

EClinicalMedicine(2022)10.1016/j.eclinm.2022.101409

N/A

1.1DataRank · unranked

37 citations

Norbert Bräu, Michael R. Waters, Ronaldo C. Go, Atul Malhotra, Bradley D. Hunter +32 more

Strategic treatment optimization for HCV (STOPHCV1): a randomised controlled trial of ultrashort duration therapy for chronic hepatitis C

Wellcome Open Research(2021)10.12688/wellcomeopenres.16594.1

N/A

0.292DataRank · unranked

6 citations

Sarah Pett, Leanne McCabe, Christopher R. Jones, Richard Gilson, Sumita Verma +20 more

Sexual and drug use risk behaviour trajectories among people treated for recent HCV infection: the REACT study

Journal of the International AIDS Society(2023)10.1002/jia2.26168

N/A

0.259DataRank · unranked

4 citations

Sebastiano Barbieri, Evan B. Cunningham, Eric Mao, Marc van der Valk, Jürgen K. Rockstroh +13 more

Highly replicating hepatitis C virus variants emerge in immunosuppressed patients causing severe disease

Nature Communications(2025)10.1038/s41467-025-67174-w

N/A

0.208DataRank · unranked

3 citations

Tomke Arand, Ha Gyu-Thomas Seong, Christian Heuss, Margaret Tulessin, Zhiqing Wang +49 more

Hepatitis C virus transmission between eight high-income countries among men who have sex with men: a whole-genome analysis

The Lancet Microbe(2023)10.1016/s2666-5247(23)00108-8

N/A

0DataRank · unranked

10 citations

Gail Matthews, Juergen Rockstroh, Tanya Applegate, Sanjay Bhagani, Andri Rauch +83 more

Reinfection incidence and risk among people treated for recent hepatitis C virus infection

AIDS(2023)10.1097/qad.0000000000003651

N/A

0DataRank · unranked

13 citations

Joanne Carson, Marc van der Valk, Jürgen K. Rockstroh, Patrick Ingiliz, Margaret Hellard +18 more

HIV/HBV coinfection remodels the immune landscape and natural killer cell ADCC functional responses

Hepatology(2024)10.1097/hep.0000000000000877

N/A

0DataRank · unranked

11 citations

Kelly da Costa, Aljawharah Alrubayyi, Jonida Kokiçi, Natasha Fisher-Pearson, Noshin Hussain +16 more

Evaluation of the Feasibility and Efficacy of Point-of-Care Antibody Tests for Biomarker-Guided Management of Coronavirus Disease 2019

The Journal of Infectious Diseases(2024)10.1093/infdis/jiae452

N/A

0DataRank · unranked

0 citations

Eleftherios Mylonakis, Robin Dewar, Barnaby Edward Young, Jacqueline Nordwall, Sanjay Bhagani +37 more

Strategic Treatment Optimization for HCV (STOPHCV1): a randomised controlled trial of ultrashort duration therapy for chronic hepatitis C

medRxiv(2021)10.1101/2021.01.22.21250208

N/A

0DataRank · unranked

0 citations

Sarah Pett, Leanne McCabe, Christopher R. Jones, Richard Gilson, Sumita Verma +20 more